Pharmaceutical Financial Journey in APAC

Background and scope

The client, a leading pharma company, wanted to launch its three brands for cardiovascular disease, osteoporosis, and oncology in the Asian Pacific market. They wanted a comprehensive assessment of the reimbursement landscape of each decided country like Australia, Thailand, China, Japan, South Korea, Singapore. They also wanted a functional model on excel with inbuilt criteria, which can give an overall estimation of Out-of-Pocket Cost and reimbursement scenarios in each country.

The client engaged Healthark Insights to assess the policy and reimbursement landscape and the out-of-pocket cost to patients for APAC countries for cardiovascular, osteoporosis, and oncology indication.

Our approach

Secondary research

We started with in-depth secondary research for each country. The secondary research includes healthcare market, government framework, reimbursement schemes, and reimbursement trends. The country’s health policy was studied thoroughly to understand the eligibility and various criteria and calculate on the same basis. Targeted research was done for prescribing pattern and consideration of hospital, physician, and pharmacist while prescribing medicine in a specified therapeutic area, also identified and analyzed market access journey of each country.

Working excel model

The Healthark team created a working excel model to calculate the out-of-pocket scenario based on selected desired criteria based on the research.

Project output

Based on our comprehensive findings and analysis, we provided the client a detailed deck summarizing reimbursement and OOP scenario for decided Asia pacific countries for cardiovascular, osteoporosis, and oncology indication. We also provided the process of medicine approval, prescribing pattern and prescribing channel, and the financial journey of medicine. We also offer the client a working excel model where the country’s OOP scenario can be depicted based on the selected criteria like country, indications, etc.